Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Amortizatization of Intangibles of $68000.0 for Q1 2026, down 87.43% on a YoY basis from $541000.0 in Q1 2025, and down 49.25% sequentially from $134000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Amortizatization of Intangibles data on file, last reported at $68000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 87.43% year-over-year to $68000.0; the trailing twelve-month figure through Mar 2026 stood at $947000.0 (down 63.49% YoY), and the FY2025 full-year result was $1.4 million, down 49.36% from the prior year.
- Amortizatization of Intangibles retreated to $68000.0 in Q1 2026, from $134000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $751000.0 in Q1 2024 to a low of -$26000.0 in Q1 2022.
- A 5-year average of $461235.3 and a median of $550000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 7757.14% in 2022 and sank 87.43% in 2026, its largest moves.
- Tracing NAUT's Amortizatization of Intangibles over 5 years: stood at $550000.0 in 2022, then climbed by 12.55% to $619000.0 in 2023, then gained by 1.45% to $628000.0 in 2024, then sank by 78.66% to $134000.0 in 2025, then tumbled by 49.25% to $68000.0 in 2026.
- Business Quant data shows NAUT's Amortizatization of Intangibles at $68000.0 in Q1 2026, $134000.0 in Q4 2025, and $306000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Nautilus Biotechnology | 212.11 Mn | 116.24 Mn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 306,000.00 |
| Sep 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 439,000.00 |
| Jun 30, 2025 | 439,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 702,000.00 |
| Jun 30, 2024 | 702,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | 619,000.00 |
| Dec 31, 2023 | 619,000.00 |